If the FDA approves a drug for a neglected tropical disease, the company gets a voucher that accelerates review of another drug. This remains controversial.

In a fit of boundless national optimism, Peugeot and Renault (and a few years later Volvo) teamed up to make a new V8 for good power and performance. But that's not what the world got. We welcomed in ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority ...

While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. Since ...

Millions of Americans report that they are unable to fill their prescriptions or are not taking their medications as prescribed because they cannot afford them, generating bipartisan interest in ...

Even in the era of the FDA's Commissioner's National Priority Voucher (CNPV) program, Jazz Pharmaceuticals is showing that traditional priority review vouchers (PRVs) can catch a pretty penny. In fact ...

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

PRV RENAMED: What's in a name? Apparently something, at least in the view of the U.S. Air Force, which says it is changing the name of the Personnel Recovery Vehicle (PRV) program to Combat Search and ...

TALLAHASSEE, FL / ACCESSWIRE / February 5, 2021 / Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other ...

DENVER, Aug. 28, 2019 /PRNewswire/ — Platte River Equity (“Platte River”) is pleased to announce the sale of its portfolio company, PRV Metals, LLC (“PRV Metals” or the “Company’), to Tinicum L.P.